🔎 Trials Near Me

Akèy › Kansè Ezofajyen › New York › Syracuse

Etid klinik pou Kansè Ezofajyen nan Syracuse, NY

4 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan ak bò kote Syracuse (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Ap rekriteFaz 1/2
  • Hematology-Oncology Associates of Central NY, P.C. ( Site 4925), East Syracuse · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05319730

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Ap rekriteFaz 1/2
  • Hematology-Oncology Associates of Central NY, P.C. ( Site 8925), East Syracuse · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06445972

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Ap rekriteFaz 1/2
  • Hematology-Oncology Associates of Central NY, P.C. ( Site 6925), East Syracuse · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06469944

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Ap rekriteFaz 1/2
  • Hematology-Oncology Associates of Central New York, Syracuse
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT03526835

Etid Kansè Ezofajyen nan lòt vil

Lòt etid nan Syracuse

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.